Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6874

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hyperkalemia
Interventions: Patiromer; Drug
Lead sponsor: Vifor Pharma, Inc.; Industry
Eligibility: 0 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Crohn Disease
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 77
States / cities: Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more

Conditions: Cervical Carcinoma
Interventions: LN-145, LN-145 + pembrolizumab; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 20 more

Conditions: Juvenile Spondyloarthritis
Interventions: Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 21 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium
Interventions: Nighttime noise & light reduction, Clustering patient-care interactions, Non-pharmacologic sleep aids, Daytime light exposure, Encourage out-of-bed activity, Medication management to support nighttime sleep; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 62,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: La Jolla, California • San Francisco, California • Orlando, Florida + 4 more

Conditions: Atrial Fibrillation
Interventions: OMNYPULSE™ Catheter with the TRUPULSE Generator; Device
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 39
States / cities: Phoenix, Arizona • Burlingame, California • Larkspur, California + 30 more

Conditions: COVID-19
Interventions: Shionogi Protease Inhibitor (S-217622), placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 103
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more

Conditions: Coronary Artery Disease
Interventions: PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 65
States / cities: Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Interventions: Cagrilintide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 25
States / cities: Concord, California • Fresno, California • Palm Springs, California + 22 more

Conditions: Polymyositis, Dermatomyositis
Interventions: Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label); Combination Product · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 43
States / cities: Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more

Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 79
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

Sleep Harmonization Via Bundled Team-Based Interventions in the ICU

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

SELUTION 4 De Novo Small Vessel IDE Trial

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)